Effects of Sustained‐Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results

TRK‐100STP, a sustained‐release preparation of the orally active prostacyclin analogue beraprost sodium, targets renal hypoxia. This study aimed to show the superiority of TRK‐100STP over placebos in patients with chronic kidney disease (with either primary glomerular disease or nephrosclerosis) to...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Therapeutic apheresis and dialysis 2020-02, Vol.24 (1), p.42-55
Hauptverfasser:	Nakamoto, Hidetomo, Yu, Xue‐Qing, Kim, Suhnggwon, Origasa, Hideki, Zheng, Hongguang, Chen, Jianghua, Joo, Kwon Wook, Sritippayawan, Suchai, Chen, Qinkai, Chen, Hung‐Chun, Tsubakihara, Yoshiharu, Tamai, Hirofumi, Song, Sang Heon, Vaithilingam, Indralingam, Lee, Kang Wook, Shu, Kuo‐Hsiung, Hok‐King Lo, Stanley, Isono, Masanao, Kurumatani, Hajimu, Okada, Kiyonobu, Kanoh, Hiroyuki, Kiriyama, Takashi, Yamada, Shunsuke, Fujita, Toshiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Beraprost CASSIOPEIR Chronic kidney disease Prostacyclin TRK‐100STP
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!